IMAX Imax Corp - 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously announced on March 30, 2026, Richard Gelfond, the Chief Executive Officer of IMAX Corporation (the “Company”), is on a temporary medical leave of absence. On April 16, 2026, the Company’s board of directors (the “Board”) appointed Robert D. Lister, the Company’s Chief Legal Officer and Senior Executive Vice President, to serve as the Company’s interim principal executive officer (“PEO”) in addition to his current duties until May 1, 2026, following which Mr. Gelfond will resume the role of PEO. Mr. Lister will not receive any additional compensation in connection with his temporary interim appointment.

Biographical and other information for Mr. Lister are set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on April 25, 2025 and are incorporated herein by reference. Mr. Lister is not a party to any arrangement or understanding pursuant to which he was appointed as interim PEO, or to any transactions required to be disclosed pursuant to Item 404(a) of Regulation S-K. The Company has not entered into, amended or modified any plan, contract, arrangement, grant or award in connection with the interim appointment of Mr. Lister. There are no family relationships between Mr. Lister and any of the Company’s other directors or executive officers.

2